Search Within

Komal Lachhman Jhaveri

Formats
  1. Meeting Abstract (121)
  2. Journal Article (92)
  3. Review (7)
  4. Editorial (2)
  5. Correspondence (1)
  6. Guidelines (1)
  7. Research Letter (1)
Groups
  1. Breast Medicine Service (225)
  2. Department of Medicine (225)
  3. Solid Tumor Oncology Division (225)
  4. GSK Faculty (59)
  5. Survivorship Research (48)
  6. Hematology-Oncology Fellows (46)

More Groups

People
  1. Shanu Modi (35)
  2. Sarat Chandarlapaty (29)
  3. Pedram Razavi (25)
  4. Clifford Hudis (24)
  5. Sujata Patil (22)
  6. Gary Ulaner (18)

More People

Years
  1. 2025 (31)
  2. 2024 (34)
  3. 2023 (17)
  4. 2022 (24)
  5. 2021 (26)
  6. 2020 (28)

More Years

Publications
  1. Journal of Clinical Oncology (66)
  2. Cancer Research (33)
  3. Annals of Oncology (22)
  4. Clinical Cancer Research (11)
  5. New England Journal of Medicine (6)
  6. European Journal of Cancer (5)

More Publications

Publishers
  1. American Society of Clinical Oncology (69)
  2. American Association for Cancer Research (49)
  3. Oxford University Press (23)
  4. Elsevier Inc. (17)
  5. Springer (7)
  6. Massachusetts Medical Society (6)

More Publishers

Results (225)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers
    Journal Article

    Harding, J. J.; Piha-Paul, S. A.; Shah, R. H.; Murphy, J. J.; Cleary, J. M.; Shapiro, G. I.; Quinn, D. I.; Braña, I.; Moreno, V.; Borad, M.; more...
    Nature Communications (2023)

    Fulltext@MSK | Save
  • The oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with hormone receptor-positive HER2-negative (HR + /HER2 −) advanced/metastatic breast cancer
    Journal Article

    Bardia, A.; Mayer, I.; Winer, E.; Linden, H. M.; Ma, C. X.; Parker, B. A.; Bellet, M.; Arteaga, C. L.; Cheeti, S.; Gates, M.; more...
    Breast Cancer Research and Treatment (2023)

    Fulltext@MSK | Save
  • Primary results from TROPiCS-02: A randomized phase 3 study of sacituzumab govitecan (SG) versus treatment of physician's choice (TPC) in patients (Pts) with hormone receptor-positive/HER2-negative (HR+/HER2-) advanced breast cancer
    Meeting Abstract

    Rugo, H. S.; Bardia, A.; Marine, F.; Cortes, J.; Schmid, P.; Loirat, D.; Tredan, O.; Ciruelos, E.; Dalenc, F.; Pardo, P. G.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Trastuzumab deruxtecan (T-DXd) combinations in patients with HER2-positive advanced or metastatic breast cancer: A phase 1b/2, open-label, multicenter, dose-finding and dose-expansion study (DESTINY-Breast07)
    Meeting Abstract

    Kolberg, H. C.; André, F.; Hamilton, E.; Loi, S.; Schmid, P.; Anders, C.; Yu, T.; Boston, S.; D'cruz, C.; Herbolsheimer, P.; more...
    Oncology Research and Treatment (2022)

    Fulltext@MSK | Save
  • persevERA Breast Cancer (BC): Phase III study evaluating the efficacy and safety of giredestrant (GDC-9545) + palbociclib versus letrozole + palbociclib in patients (pts) with estrogen-receptor-positive, HER2-negative locally advanced or metastatic BC (ER+/HER2– LA/mBC)
    Meeting Abstract

    Müller, V.; Turner, N.; Jhaveri, K.; Bardia, A.; Niikura, N.; Diéras, V.; Barrios, C.; Im, S. A.; Bellet, M.; Chang, C. W.; more...
    Oncology Research and Treatment (2022)

    Fulltext@MSK | Save
  • Overall survival (OS) results from the phase III TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician's choice (TPC) in patients (pts) with HR+/HER2-metastatic breast cancer (mBC)
    Meeting Abstract

    Rugo, H. S.; Bardia, A.; Marme, F.; Cortes, J.; Schmid, P.; Loirat, D.; Tredan, O.; Ciruelos, E. M.; Dalenc, F.; Pardo, P. G.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Preliminary results from a phase I study using the bispecific, human epidermal growth factor 2 (HER2)-targeting antibody-drug conjugate (ADC) zanidatamab zovodotin (ZW49) in solid cancers
    Meeting Abstract

    Jhaveri, K.; Han, H.; Dotan, E.; Oh, D. Y.; Ferrario, C.; Tolcher, A.; Lee, K. W.; Liao, C. Y.; Kang, Y. K.; Kim, Y. H.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Sacituzumab govitecan (SG) efficacy in hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer (MBC) by HER2 immunohistochemistry (IHC) status in the phase III TROPiCS-02 study
    Meeting Abstract

    Schmid, P.; Cortés, J.; Marmé, F.; Rugo, H. S.; Tolaney, S. M.; Oliveira, M.; Loirat, D.; Jhaveri, K.; Yoon, O. K.; Motwani, M.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Primäre ergebnisse der TROPiCS-02: Eine randomisierte phase 3 studie mit sacituzumab govitecan vs. behandlung nach wahl des arztes (TPC) bei patienten mit hormonrezeptor-positivem/HER2-negativem (HR+/HER2-) fortgeschrittenem mammakarzinom
    Meeting Abstract

    Marmé, F.; Rugo, H. S.; Bardia, A.; Cortes, J.; Schmid, P.; Loirat, D.; Tredan, O.; Ciruelos, E.; Dalenc, F.; Gómez Pardo, P.; more...
    Oncology Research and Treatment (2022)

    Fulltext@MSK | Save
  • Targeting insulin feedback to enhance alpelisib (TIFA): A phase II randomized trial in metastatic, PIK3CA-mutant, hormone receptor-positive breast cancer
    Meeting Abstract

    Shen, S.; Salehi, E.; Farooki, A.; Flory, J.; Williams, D.; Carpio, A.; Chang, C.; Lacouture, M. E.; Andreopoulou, E.; Sardesai, S. D.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save